German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

Suggested remit: To appraise the clinical and cost effectiveness of spesolimab within its marketing authorisation for treating generalised pustular psoriasis flares in adults.

BURLINGTON, ON, Feb. 5, 2025 /CNW/ - Boehringer Ingelheim Canada announces that intravenous and subcutaneous supplies of SPEVIGO ® (spesolimab injection/spesolimab for injection) are now available in ...